Monoclonal antibody (mAb) product innovation aim of facility expansion in KansasAugust 23, 2024A $130-million investment through 2026 is expected to bolster production and development of monoclonal antibody-based therapy, including a potential product in canine dermatology.
SPONSORED CONTENTYear-Round Tick Control is ImportantEmpower dog owners to protect their dogs with protection approved by the FDA for the prevention of Lyme infections in dogs as a direct result of killing black-legged ticks. + Learn More